The aim of the study was to investigate the potential of synaptotagmin-1 as a CSF biomarker in dementia due to Alzheimer’s disease and in MCI due to Alzheimer’s disease. The gene discussed is SYT1; the disease is early-onset autosomal dominant Alzheimer disease.